Today was the day announced for a decision to be made.
The HSE’s Senior Management Team have approved the reimbursement of Skyclarys for patients with Friedreich’s Ataxia.
Today (25 August) was the day announced for a decision to be made.
HSE senior management met to discuss providing Skyclarys, as Biogen had made a new offer to the Health Service.
The outcome will result in strong engagement with Biogen over the coming years in respect of the treatment of Friedreich’s Ataxia.
The HSE's Drugs Group earlier this month recommended the drug not be reimbursed, over cost-effectiveness concerns.
Skyclarys is the first treatment for the condition, which is shown to slow the symptoms by up to 50pc.
Kfm news had previously spoken to Niamh Ní Hoireabhaird about her experiences with FA, and Craig Coady, a father of two teenage boys have suffered with the disease, one of whom sadly passed away as a result.
The progressive neuro muscular disease causes nerve damage, muscle weakness and mobility loss.
Approximately 200 people are affected by the disease in Ireland.
Daniel Kinahan Set To Apply For Bail
Former Swimming Coach George Gibney Jailed For Over 15 Years For Sexual Abuse Of Children
Robert Pether Returning To Ireland After Five-Year Iraqi Detention
Over 23,000 Teachers Beginning Industrial Action Today
New Funding Announced For Youth Services And Counselling In Kildare On World Mental Health Day
Jury In Triple Murder Trial Of Louth Family Sent Home
Families Face Delays Arranging Funerals Amid Pressure On Post-Mortem Services
